RxDoctor Payments DataLook up a doctor →

David Hakimian, MD

Hematology & Oncology · Niles, ILNPI 1972590347

Payments from drug & device makers

$2,625,753in general payments, 2019–2025

Across 1,321 payments — averaging $1987.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirati Therapeutics, Inc.$1.5M
  • Daiichi Sankyo Inc.$417K
  • E.r. Squibb & Sons, L.L.C.$189K
  • AstraZeneca$161K
  • Genentech, Inc.$124K
  • Amgen$52K
  • plus $142K from 54 others
$3,900in research payments, 2019–2025

Across 7 payments — averaging $557.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Scientific Affairs, LLC$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mirati Therapeutics, Inc.261$1,540,318
Daiichi Sankyo Inc.343$416,930
E.r. Squibb & Sons, L.L.C.63$189,325
AstraZeneca(2 entities)46$161,041
Genentech, Inc.42$123,972
Amgen19$51,759
Puma Biotechnology, Inc.16$44,646
Janssen Research & Development, LLC8$32,500
GSK26$24,355
Pfizer52$20,790
Eli Lilly3$4,087
Janssen Scientific Affairs, LLC28$2,467
Lilly USA, LLC10$1,962
Bristol Myers Squibb20$1,425
Novartis71$1,286
Merck35$888
Boehringer Ingelheim4$826
Johnson & Johnson(2 entities)24$530
Biontech SE3$429
Incyte Corporation18$389
Takeda Pharmaceuticals U.S.A., Inc.10$378
Gilead(2 entities)16$348
AbbVie15$337
Octapharma USA, Inc.3$330
Genentech USA, Inc.14$286
Sanofi14$283
Astellas Pharma US Inc8$254
Seagen Inc.11$251
Regeneron Healthcare Solutions, Inc.7$225
Eisai Inc.10$220
Servier Pharmaceuticals LLC9$204
Jazz Pharmaceuticals Inc.6$195
W. L. Gore & Associates, Inc.1$163
ADC Therapeutics America, Inc.4$156
EMD Serono, Inc.7$153
Bayer7$152
Pharmacyclics LLC, An Abbvie Company7$143
Agios Pharmaceuticals, Inc.5$137
Karyopharm Therapeutics Inc.5$118
G1 Therapeutics, Inc.5$112
Tersera Therapeutics LLC3$104
Deciphera Pharmaceuticals Inc.4$98
Springworks Therapeutics, Inc.3$93
Rigel Pharmaceuticals, Inc.4$82
Morphosys, US Inc.4$69
Array Biopharma Inc3$64
AVEO Pharmaceuticals, Inc.3$61
Pharmaessentia USA Corporation2$59
Exelixis Inc.2$50
Blueprint Medicines Corporation2$49
Geron Corporation2$47
Stemline Therapeutics Inc.2$46
EUSA Pharma (US) LLC2$45
Taiho Oncology, Inc.2$44
Fennec Pharmaceuticals, Inc.2$42
Adaptive Biotechnologies Corporation1$41
Genmab U.S., Inc.2$40
Kyowa Kirin, Inc.2$39
Kvk-tech, Inc.7$33
Sanofi-aventis U.S. LLC1$28

How this compares

$2,625,753 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024
$3,178,246
Medicare patients
506
Services billed
78,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Niles

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →